Pieris Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Palvella Therapeutics has issued its 2026 proxy statement detailing director elections, executive compensation, and a proposal to increase equity incentive plan shares.
Palvella Therapeutics will hold its annual stockholder meeting virtually on June 10, 2025, to vote on director elections, auditor ratification, and executive compensation.
Palvella Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, focusing on director elections, auditor ratification, and executive compensation.
Pieris Pharmaceuticals will hold its 2024 annual meeting of stockholders virtually on December 2, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.